Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy decreases cardiovascular morbidity and mortality in patients with heart failure (HF). Evidence-based HF guidelines support the titration of RAASi to achieve
target doses to optimize treatment benefits. However, RAASi also increases the risk of hyperkalemia. Hyperkalemia, an electrolyte disorder characterized by elevated levels of serum potassium, is a barrier to optimization of RAASi therapy in patients with HF. Unfortunately, down-titration or discontinuation of RAASi treatment is a common strategy to manage hyperkalemia in routine clinical practice; these actions place HF patients at increased risk
of major adverse clinical events. Novel potassium binders effectively and safely lower serum potassium, potentially enabling HF patients to remain on optimal RAASi therapy.

Date: Wednesday, January 15, 2025
Time: 2:00 PM - 3:00 PM ET
Where: Virtual; OnDemand in the HFSA Learning Center to follow

This educational activity is presented through a collaboration between Voxmedia and the Heart Failure Society of America. The program topic, learning objectives, and faculty have been reviewed and approved by HFSA.

Please note: Registration link won't be live until the event begins.